Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS ziltivekimab after acute myocardial infarction
NL-OMON59392Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Ziltivekimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Time to first occurrence of 4-component MACE, Number of 4-component MACE events and 7 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON59392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59392.